Immutep Ltd has released a press release.
Immutep granted Australian patent for eftilagimod alpha
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Immutep completes recruitment of initial NSCLC cohort
- First patient dosed in INSIGHT-004
- Immutep granted European patent for eftilagimod alpha
- More mature positive data for TACTI-mel trial presented
- Immutep granted US patent for IMP321
Later from Immutep
- Immutep completes recruitment of AIPAC trial in MBC
- Immutep Entitlement Offer Booklet
- Entitlement Offer Results & Shortfall Notification
- Appendix 4E & 2019 Full Year Statutory Accounts
- Immutep granted European patent for IMP321 in cancer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep